Integrated Biopharma Inc.
- INBP · OTC
- Pharmaceutical Preparations
- Hillside, NJ
- 134 employees
- CIK 0001016504
Updated from SEC filings through
Top things to know
Executives
- Christina Kay Co-Chief Executive Officer 4, 2025-12-10
- Sheppard Riva Co-Chief Executive Officer 4, 2025-12-10
- Dina Masi Chief Financial Officer 4, 2025-12-10
Integrated Biopharma Inc is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Hillside, NJ. It trades as INBP on OTC. Revenue was $43.9M in the fiscal year ending June 30, 2026, -19.3% from the year before. It reported about 134 employees. Christina Kay is Co-Chief Executive Officer.
Five-year financials
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $43.9M 10-K, 2026-09-25 | $54.4M 10-K, 2026-09-25 | $50.3M 10-K, 2025-09-23 | $50.7M 10-K, 2024-09-20 | $56.2M 10-K, 2023-09-15 |
| Operating income | -$2.7M 10-K, 2026-09-25 | $2.0M 10-K, 2026-09-25 | $251K 10-K, 2025-09-23 | $120K 10-K, 2024-09-20 | $2.7M 10-K, 2023-09-15 |
| SG&A | $3.5M 10-K, 2026-09-25 | $3.5M 10-K, 2026-09-25 | $3.6M 10-K, 2025-09-23 | $3.9M 10-K, 2024-09-20 | $3.8M 10-K, 2023-09-15 |
| Net income | -$2.8M 10-K, 2026-09-25 | $808K 10-K, 2026-09-25 | $112K 10-K, 2025-09-23 | -$34K 10-K, 2024-09-20 | $3.8M 10-K, 2023-09-15 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Christina Kay | Co-Chief Executive Officer | 4, 2025-12-10 |
| Sheppard Riva | Co-Chief Executive Officer | 4, 2025-12-10 |
| Dina Masi Chief Financial Officer at Integrated BioPharma, Inc. | Chief Financial Officer | 4, 2025-12-10 |
What Integrated Biopharma Inc does
, a Delaware corporation (together with its subsidiaries, the “Company”), is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States and Luxembourg.
Shares and governance
| Shares outstanding | 31.1 million (as of September 23, 2026) | 10-K, September 25, 2026 |
|---|---|---|
| Public float | $3.4M (as of December 31, 2025) | 10-K, September 25, 2026 |
| Reportable segments | 2 (period ending June 30, 2026) | 10-K, September 25, 2026 |
| Latest proxy statement | Meeting October 28, 2026 (filed October 28, 2026) | DEF 14A, October 28, 2026 |
| Auditor | CBIZ CPAs P.C. (Morristown, New Jersey) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-09-25
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-20
- Item 8.01 Other events
- 8-K filed 2026-07-02
- Item 1.01 Entry into a material definitive agreement
- Item 1.02 Termination of a material definitive agreement
- 8-K filed 2026-05-08
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-15
- Item 8.01 Other events
- 8-K filed 2026-02-18
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-02-11
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-12-01
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2025-11-10
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-09-23
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Integrated Biopharma Inc
- What does Integrated Biopharma Inc do?
- In its own words, from Item 1 of its 10-K: ", a Delaware corporation (together with its subsidiaries, the “Company”), is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States and Luxembourg."
- What is Integrated Biopharma Inc's revenue?
- $43.9M for the fiscal year ending June 30, 2026, from its 10-K filed September 25, 2026.
- Is Integrated Biopharma Inc profitable?
- Integrated Biopharma Inc reported net income of -$2.8M for the fiscal year ending June 30, 2026.
- How many employees does Integrated Biopharma Inc have?
- About 134 as of June 30, 2026, as stated in its annual report.
- Who is the CEO of Integrated Biopharma Inc?
- Christina Kay, Co-Chief Executive Officer, as named in a 4 filed December 10, 2025.
- Who is the CFO of Integrated Biopharma Inc?
- Dina Masi, Chief Financial Officer, as named in a 4 filed December 10, 2025.
- Where is Integrated Biopharma Inc headquartered?
- Hillside, NJ.
- What is Integrated Biopharma Inc's stock ticker?
- INBP on OTC.
- What industry is Integrated Biopharma Inc in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Integrated Biopharma Inc's website?
- ibiopharma.com. Investor relations: https://ir.ibiopharma.com/.
- When does Integrated Biopharma Inc report earnings next?
- November 11, 2026. Source: estimate_10q_cadence.
- Is Integrated Biopharma Inc a public company?
- Yes. Integrated Biopharma Inc files with the SEC under CIK 0001016504 and trades as INBP.
- Who audits Integrated Biopharma Inc?
- CBIZ CPAs P.C., Morristown, New Jersey, as named in its latest annual report (10-K).
- How many shares of Integrated Biopharma Inc are outstanding?
- 31.1 million shares as of September 23, 2026, from its 10-K filed September 25, 2026.
- What is Integrated Biopharma Inc's public float?
- $3.4M as of December 31, 2025, as reported on the cover of its 10-K filed September 25, 2026.
- How many business segments does Integrated Biopharma Inc report?
- 2 reportable segments for the period ending June 30, 2026, from its 10-K filed September 25, 2026.
- When is Integrated Biopharma Inc's annual shareholder meeting?
- October 28, 2026, per its proxy statement (DEF 14A) filed October 28, 2026.